Unregistered User If this is not your name, click here.
		Contact Us | Order Now | Journals | Bookstore | Register a colleague
	Select a ChannelAcneAIDS and HIVAllergy OtherAlzheimer'sAnaesthesiology OtherAngina Pectoris/MIAnxietyArthritis OtherAsthmaBack PainBacterial InfectionsBladder CancerBone Marrow TransplantationBreast CancerCardiology OtherCataractCell TransplantationCervical CancerCholesterol/Lipid disordersCirrhosisClinical PharmacologyColorectal CancerCongestive Heart FailureContact DermatitisContraceptionCOPDCystic FibrosisDental and Oral DisordersDepressionDermatology OtherDiabetesDialysisEating DisordersElbowEmergency MedicineEndocrinology OtherEpilepsyErectile DysfunctionFibromyalgiaGastro OtherGeneticsGenitourinary OtherGeriatricsGERD/GastritisGlaucomaH. Pylori/UlcerHaematology OtherHair LossHeadachesHepa/Biliary OtherHepatitisHipHRTHypertensionIBDImmunologyInfectious OtherInfertilityIntensive CareIrritable Bowel SyndromeKneeLeukemiasLiver CancerLung CancerLupusLymphomasMelanomaMenopauseMultiple Sclerosis Nephrology OtherNeurologic OtherNutritional / Metabolic OtherOb/Gyn OtherObesityOncology OtherOphth. OtherOphthalmic SurgeryOrgan TransplantationOrthopaedics OtherOsteoarthritisOsteoporosisOtitisOtorhino. OtherOvarian CancerPaediatricsPainPancreatic CancerParkinson'sPregnancyProstate CancerPsychiatry OtherPulmonary OtherRadiologyRenal CancerRenal FailureRespiratory InfectionsRheumatoid arthritisRheumatology OtherRhinitisSchizophreniaShoulderSleep ApnoeaSleep DisordersSpineStrokeSTDsSurgeryThyroid DisordersTransfusionTransplant Surgery OtherTraumaUrinary IncontinenceUrinary tract infectionsVaccinologyVascular DisordersViral Infections

SEARCH   News Bookstore Medline The Web Meetings & Congresses Complete Doctor's Guide    EXPLORE :    All News   All Webcasts   All Cases   All Meetings & Congresses   All Medical Resources New drugs / indications English Dictionary Medical Dictionary Thesaurus Warning | Privacy | Awards  Favourite Journals  Click here to choose your favourite journals  Favourite Sites  Click here to choose your favourite sites  Languages  Select languageEnglishFrançais

FDA Approves Duloxetine HCl for the Management of Fibromyalgia NEW YORK -- June 16, 2008 -- The US Food and Drug Administration (FDA) has approved duloxetine HCl (Cymbalta) for the management of fibromyalgia, a chronic widespread pain disorder. Duloxetine HCl is a serotonin-norepinephrine reuptake inhibitor indicated to reduce pain in patients with fibromyalgia. Duloxetine HCl was proven efficacious in 3 pivotal 3-month clinical trials involving 874 patients with fibromyalgia. In both studies, duloxetine HCl reduced pain at the study's endpoint compared with placebo as measured by the Brief Pain Inventory (BPI) 24-hour average pain scale. Significant improvement in pain for duloxetine HCl versus placebo was observed in the first week of each study. Fifty-one percent and 55% of patients on duloxetine HCl had a 30% improvement on the BPI at the study's endpoint. In addition, 65% and 66% of patients taking duloxetine HCl 60 mg daily reported feeling better at the study's endpoint as measured by the Patient Global Impression of Improvement (PGI-I). Duloxetine HCl 60 mg was also superior to placebo on the Fibromyalgia Impact Questionnaire Total Score. In 4 pooled studies, the most commonly observed adverse events in duloxetine HCl-treated patients with fibromyalgia were nausea, dry mouth, constipation, decreased appetite, sleepiness, increased sweating, and agitation. In the placebo-controlled clinical trials, the overall discontinuation rates due to adverse events for duloxetine HCl versus placebo were 20% and 12%, respectively. The approval marks the fourth disorder that the FDA has approved for duloxetine HCl. In addition to fibromyalgia, duloxetine HCl is approved for the management of diabetic peripheral neuropathic pain (DPNP) and the treatment of major depressive disorder and generalised anxiety disorder, all in adults aged 18 years and older. SOURCE: Chamberlain Healthcare Public Relations E-mail this page to a friend or colleague! To print, use this version